SCHEMBL4772801

SCHEMBL4772801

NCCCc1ncccc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.46
KAT2B Q92831 2/20 0.45
POLB P06746 1/20 0.45
CYP1A2 P05177 3/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 3/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C9 P11712 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2A6 P11509 1/20 0.41
MET P08581 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11608238 0.95 PDE10A (0.45) PDE10AKAT2BPOLBCYP1A2TSHR
SCHEMBL8385464 0.83 PDE10A (0.51) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL8600289 0.83 PKM (0.46) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL18962665 0.81 PKM (0.45) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL9656794 0.80 FFAR1 (0.52) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL11097786 0.80 ALDH1A1 (0.43) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL9591091 0.80 PKM (0.52) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL6369459 0.80 PDE10A (0.49) PDE10APOLBCYP1A2TSHRMAPT
SCHEMBL27679418 0.80 PDE10A (0.49) PDE10APOLBCYP1A2TSHRMAPT
Hydrochloric Acid SCHEMBL11089348 0.79 ALDH1A1 (0.42) PDE10APOLBCYP1A2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322309-B1 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2008-08-13 EP disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-20070027158-A1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION 2007-02-01 US disclosed
US-6884815-B1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2005-04-26 US disclosed
EP-1322309-A4 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2004-10-13 EP disclosed
US-6723743-B1 TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS NEUROGEN CORPORATION 2004-04-20 US disclosed
EP-1322309-A2 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2003-07-02 EP disclosed
WO-2002049993-A2 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027158-A1 High affinity small molecule C5a receptor modulators C3AR1, C5AR1, C5AR2 PDE10A 2159/4885KAT2B 3911/4885POLB 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.